• Target

    £1,000,000

  • Type

    Equity

  • Close Date

    Oct 31 2018

  • Status

    Live

RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme. Please read FULL risk warning.

Ambicare Health

Ambicare Health Ltd has developed a portfolio of wearable light sources for medical and consumer healthcare applications.

Investment closes only once the total pledged amount passes the minimum of £400,000

Total Pledged: £597,337
Max

£1,000,000

A pledge is not a commitment. You will be asked to confirm in the next section.

Track
Contact
Companies
House
Twitter

Overview

Acne is a common skin condition that affects 80% of 11-30 year
olds. There are a number of therapeutic and over the counter (OTC) treatments available however many of the therapies fail to deliver effective treatment or manage the symptoms of acne. There is also a growing concern about chemicals used in certain treatments and the dangerous side effects this can cause. For this reason, acne sufferers are beginning to turn to phototherapy devices. Ambicare Health has identified the issues caused by the current devices and has introduced the first hands free blue light emitting device, allowing users complete freedom to do other things whilst undergoing treatment to heal and eliminate acne.

Ambicare Health is a company that has spun out of the University of St. Andrews and the Ninewells Hospital and Medical School in 2004. Ambicare has made significant progress in the development and commercialisation of the wearable and light emitting diode (LED) based devices with a range of medical and consumer healthcare applications. Whilst using blue light therapy to treat acne is not a new concept, Ambicare have been the first to introduce handsfree devices that can be used at home or away from home called Lustre Pure Light. The technology to make Lustre derived from Ambicare’s first product, Ambulight PDT, which was used to successfully cure forms of skin cancer. While the Lustre product range has gained significant interest and highly satisfied its users, Ambicare identified that its existing products are expensive to manufacture and thus expensive to sell. This has resulted in Ambicare releasing a new product in the Lustre product range, Lustre Solo.

Ambicare has a revenue generating product portfolio, with key sales channels through Boots and Amazon. 
Ambicare solo female
Deal Manager avatar

Deal Manager
Agne Pakalniskyte

  • Sector: Healthcare
  • Region: Scotland
  • Stage: Early stage - early revenues, pre-profit
  • Eligible Tax: EIS
  • Board Requirement: Board In Place
  • Pre Money Valuation: £4,800,000
  • Originator: Envestors
This section is currently locked.
Please Sign Up or Log In to unlock.

Team

This section is currently locked.
Please Sign Up or Log In to unlock.

Market

This section is currently locked.
Please Sign Up or Log In to unlock.

Investment

This section is currently locked.
Please Sign Up or Log In to unlock.

Discussions

This section is currently locked.
Please Sign Up or Log In to unlock.

Deal documents

This section is currently locked.
Please Sign Up or Log In to unlock.

Originator


Originator: Envestors

Investment Focus: Equity and Debt

About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing a minimum of £25,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding. Envestors是英国受FCA监管的企业金融顾问同时运营着一个国际化的资深投资人网络,为高速发展的公司寻求最低为£25,000的现金投资,£250,000到£2m的股权投资。

Contact Name: Oliver Woolley

  • Registered Investors
    Over 1000
  • Investment through platform
    Over £100m